IL22 and graft versus host disease: Recombinant human IL-22 is currently in Phase II clinical trials for the treatment of COVID-19 pneumonia, acute pancreatitis, chronic acute liver failure, alcoholic hepatitis, and graft-versus-host disease (GVHD) (NCT02406651).